Overview

Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
A Phase 1, open-label, dose escalation, multi-center study in patients who have been diagnosed with multiple myeloma and who have relapsed or have refractory/relapsed disease after treatment with at least 2 prior therapies.
Phase:
Phase 1
Details
Lead Sponsor:
La Jolla Pharmaceutical Company
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate